Prostatic NeoplasmsPROTEUS Trial: Neoadjuvant Apalutamide Plus ADT in High-Risk Prostate Cancer
The PROTEUS trial investigated neoadjuvant apalutamide plus ADT for high-risk localised prostate cancer, showing improved pathologic complete response rates.